SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively trending as market participants analyze former President Trump's speech at the World Economic Forum in Davos. His remarks, particularly those concerning Greenland and the broader economic outlook, are sparking intense debate within the community. Discussion centers on whether his bullish pronouncements or controversial international rhetoric will ultimately dictate market sentiment amid geopolitical tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's special address at the World Economic Forum is generating intense discussion around DJT, with market participants keenly focused on his comments regarding tariffs and the proposed acquisition of Greenland. The community is actively debating the potential for global economic repercussions, as some express concern about market instability and a 'Sell America' trade, while others praise his disruptive approach to international policy.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after an earnings report that, despite exceeding estimates, has sparked significant debate regarding subscriber growth, cautious guidance, and the strategic implications of its potential Warner Bros. Discovery acquisition. While many view the current dip as an oversold buying opportunity for a market leader, concerns around debt, a paused buyback program, and slower growth are driving a bearish outlook, with the community sharply divided on the stock's immediate future.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, was awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development has ignited widespread community discussion, with many highlighting the stock's low share float and speculating about a potential short squeeze, drawing parallels to other recent volatile small-cap movements. Community members are actively debating the contract's impact on PAVmed's valuation, especially given its significant ownership stake in Lucid.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid an intense geopolitical spotlight on Greenland's strategic rare earth minerals, fueled by recent statements from a former President emphasizing the territory's importance for national security. The community is actively discussing significant price volatility and potential market manipulation, with many anticipating a major business update from the company as a key catalyst. This narrative positions CRML as a central player in securing a Western critical minerals supply chain, driving strong bullish sentiment among investors despite recent fluctuations.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to widespread market discussion around geopolitical tensions, specifically former President Trump's rhetoric on Greenland and trade policy during his Davos address. The community is actively debating whether perceived softening in his stance will alleviate pressure or if broader concerns over trade relations and central bank policy will continue to influence growth-oriented tech assets.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing intense community discussion, fueled by recent high-grade silver drill results and a broadly bullish sentiment across precious metals markets. Investors are actively debating the company's valuation, weighing its significant resource potential and strategic investor interest against its current pre-production status and capital requirements.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community reacts to its announced plans for a new rare earth metals and alloys production facility in France, securing substantial government backing. This development is seen as a pivotal step in establishing independent rare earth supply chains, aligning with growing geopolitical emphasis on national security and domestic sourcing away from China. Investors are actively discussing USAR's role in supplying critical materials for electric vehicles, defense, and advanced technology.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

Aqua Metals is trending after announcing a multi-year supply agreement with 6K Energy, reinforcing its position in domestic battery material commercialization. This news has sparked significant bullish momentum and speculation around its low float; however, a vocal segment of the community expresses skepticism, citing the company's history of frequent stock dilution and reverse splits. The broader conversation reflects ongoing interest in critical mineral recycling and securing US supply chains.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing intense discussion driven by former President Trump's remarks from Davos, emphasizing his supportive stance towards the crypto industry and potential legislative action. This has polarized the community, with many anticipating a major rally and a "super cycle" in digital assets, while a segment expresses caution, labeling recent price action as a "bear trap" amid ongoing market volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Daily Wegovy pill brings GLP-1 weight loss treatment to U.S. adults

When I first started following news about GLP 1 drugs, everything revolved around injections that patients had to store, handle, and learn to use correctly. Now the arrival of a Wegovy pill in U.S...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Equity

LifeMD Adds Novo Nordisk's Weight-loss Pill Wegovy To Telehealth Platform

(RTTNews) - LifeMD, Inc. (LFMD), a provider of virtual primary care and pharmacy services, on Monday said it is now offering Novo Nordisk's Wegovy pill for chronic weight management and...

LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One...

HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand

Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.

Insider Selling: LifeMD (NASDAQ:LFMD) CMO Sells 15,000 Shares of Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of...

Jessica Friedeman Sells 15,000 Shares of LifeMD (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CMO Jessica Friedeman sold 15,000 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of...

LifeMD, Inc. (NASDAQ:LFMD) Receives Average Recommendation of "Hold" from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have been given a consensus rating of "Hold" by the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Two...

Hims & Hers Expands Care Scope as Prescription Platforms Evolve

HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.

FY2025 Earnings Estimate for LifeMD Issued By HC Wainwright

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for LifeMD in a research note issued to investors on...

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.06	--	--	N/A
Q3 '25	-$0.02	-$0.10	-400.00%	MISSED
Q2 '25	-$0.01	-$0.06	-620.03%	MISSED
Q1 '25	-$0.05	$0.01	118.92%	BEAT
Q4 '24	-$0.05	-$0.02	61.11%	BEAT

LFMD
LifeMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest LFMD News

LFMDLifeMD Inc